Immunomedics, Inc. (NASDAQ: IMMU) is committed to being a leading, innovative biopharmaceutical company dedicated to improving a patient’s health and quality of life with novel antibody–based therapeutics for the treatment of cancer, autoimmune and other serious diseases. The company’s work is driven by scientific excellence and the highest standards in a culture of integrity, pride and dedication. In doing so, Immunomedics creates value for its shareholders and a rewarding environment for its employees. For more information, visit the company’s website at www.immunomedics.com.
Immunomedics (IMMU) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option